Pre-market most active 4564.T OncoTherapy (JPX) JPY 21.00 Feb 2026: watch vol
In the pre-market session we see 4564.T stock trading at JPY 21.00, with heavy volume that places the name among the most active issues on the JPX today. Volume is already at 34,217,200.00, well above typical intraday flows and above the 50-day average price of 20.96. Traders cite near-term clinical and funding updates as the likely drivers. We provide a concise pre-market read on valuation, technical setup, and analyst-relevant metrics to help frame early trading decisions.
Pre-market snapshot for 4564.T stock
OncoTherapy Science, Inc. (4564.T) is quoted on the JPX at JPY 21.00 with an open of 22.00 and a day range of 21.00–22.00. Market cap is JPY 7,216,515,579.00 and shares outstanding are 343,643,599.00.
Volume and trading interest
Volume of 34,217,200.00 is about 76.12% of the average volume of 44,940,955.00, which flags genuine market attention. High relative volume on pre-market prints often precedes wider intraday moves when catalysts are present.
Fundamentals and valuation
Last reported EPS is -2.83 and reported PE is -7.42, reflecting ongoing losses in a clinical-stage biotech. Price-to-book stands at 3.54 and price-to-sales at 9.20, signaling a premium to revenue given development-stage risks.
Technical setup and momentum
Momentum indicators show a neutral to mild positive bias: RSI 53.18, MACD histogram 0.11, and Bollinger middle band 20.55. The stock sits just above its 50-day average of 20.96 and below the 200-day average of 24.03, suggesting short-term stability but a longer-term downtrend.
Meyka AI rates 4564.T with a score out of 100
Meyka AI rates 4564.T with a score out of 100: 69.25 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are model outputs and do not constitute investment advice.
Meyka AI’s forecast model projects near-term and medium-term levels
Meyka AI’s forecast model projects a monthly price of JPY 16.39 and a one-year projection of JPY 18.02. Versus the current price of JPY 21.00, the one-year projection implies a downside of about -14.10%. Forecasts are model-based projections and not guarantees.
Final Thoughts
Key takeaways for 4564.T stock: the pre-market picture shows JPY 21.00 and unusually high volume at 34,217,200.00, which makes the issue one of the most active names on the JPX this morning. Fundamentals show a clinical-stage biotech profile with EPS -2.83, negative PE and elevated price-to-sales and price-to-book multiples versus revenue and book value. Technicals are mixed: short-term momentum is flat to slightly positive while the 200-day average of 24.03 remains overhead. Meyka AI’s model projects a one-year figure of JPY 18.02, implying roughly -14.10% versus today, and our grade is 69.25 (B, HOLD). Investors should weigh trial readouts, cash runway and sector trends in Healthcare before acting. For rapid intraday moves, watch evolving volume and any JPX notices or company updates that could change the clinical or funding outlook. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts and grades are model outputs, not guarantees or financial advice.
FAQs
What is driving the pre-market activity in 4564.T stock?
Pre-market activity in 4564.T stock is driven by elevated volume of 34,217,200.00 and anticipation of clinical updates and funding news. In clinical biotechs, newsflow often concentrates trading before the cash market opens.
How does OncoTherapy’s valuation look versus peers?
OncoTherapy (4564.T stock) shows high price-to-sales 9.20 and price-to-book 3.54, which are rich relative to larger healthcare peers. The company remains loss-making with EPS -2.83, so comparatives depend heavily on trial outcomes.
What is Meyka AI’s short-term forecast for 4564.T stock?
Meyka AI’s forecast model projects a monthly price of JPY 16.39 and a one-year projection of JPY 18.02 for 4564.T stock. These are model projections and not guarantees; downside versus the current price is about -14.10% for the one-year figure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.